Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTNI91K)

• DTT Name: Melanocortin receptor 3 (MC3R) DTT Info
• Gene Name: MC3R

Molecule-Related Drug & Molecule List

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melanotetan II	DMYK8MV	Obesity	5B81	Preclinical	[1]

47 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ac-dR[CEHdFRWC]-NH2	DM7XY41	Discovery agent	N.A.	Investigative	[2]
Ac-His-D-Phe-Arg-2-Nal-NHCH3	DMAQR29	Discovery agent	N.A.	Investigative	[3]
Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2	DMOVI7Y	Discovery agent	N.A.	Investigative	[4]
Ac-R[CEHdFRWC]-NH2	DMBFUD0	Discovery agent	N.A.	Investigative	[2]
Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3	DMIH5CD	Discovery agent	N.A.	Investigative	[3]
Ac-YCit[CEHdFRWC]-NH2	DMAVPXL	Discovery agent	N.A.	Investigative	[2]
Ac-YK[CEHdFRWC]-NH2	DM5SJX8	Discovery agent	N.A.	Investigative	[2]
Ac-YRC(Me)*EHdFRWC(Me)NH2	DMWJ8UR	Discovery agent	N.A.	Investigative	[2]
Ac-YRMEHdFRWG-NH2	DMN2UKC	Discovery agent	N.A.	Investigative	[2]
Ac-YRMEHdFRWGSPPKD-NH2	DMDH5B3	Discovery agent	N.A.	Investigative	[2]
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	DMVQ4KG	Discovery agent	N.A.	Investigative	[2]
Ac-YR[CEH(pCl-dF)RWC]-NH2	DM25JXM	Discovery agent	N.A.	Investigative	[2]
Ac-YR[CEH(pF-dF)RWC]-NH2	DMXCF9T	Discovery agent	N.A.	Investigative	[2]
Ac-YR[CEHdFRWC]-NH2	DMBMY73	Discovery agent	N.A.	Investigative	[2]
Ac-YR[CEHdFRWC]SPPKD-NH2	DMDO468	Discovery agent	N.A.	Investigative	[2]
Ac-[CEHdFRWC]-NH2	DMRLOGP	Discovery agent	N.A.	Investigative	[2]
AEKKDEGPYRMEHFRWGSPPKD	DMZ8SV3	Discovery agent	N.A.	Investigative	[2]
C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2	DMHARQX	Discovery agent	N.A.	Investigative	[5]
C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2	DMI3CSJ	Discovery agent	N.A.	Investigative	[5]
C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	DMYPHVC	Discovery agent	N.A.	Investigative	[5]
C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2	DM0VP79	Discovery agent	N.A.	Investigative	[5]
C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2	DM1VCJP	Discovery agent	N.A.	Investigative	[5]
C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2	DM8AMGF	Discovery agent	N.A.	Investigative	[5]
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	DMD6OW4	Discovery agent	N.A.	Investigative	[5]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	DMX7IVO	Discovery agent	N.A.	Investigative	[6]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	DMUESCH	Discovery agent	N.A.	Investigative	[6]
C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2	DM8SXLR	Discovery agent	N.A.	Investigative	[6]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	DMM19SJ	Discovery agent	N.A.	Investigative	[6]
C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2	DMSGWZE	Discovery agent	N.A.	Investigative	[6]
C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2	DMHNCAG	Discovery agent	N.A.	Investigative	[6]
C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2	DMVWOPG	Discovery agent	N.A.	Investigative	[6]
C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2	DM36HBK	Discovery agent	N.A.	Investigative	[6]
C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2	DM5HRNM	Discovery agent	N.A.	Investigative	[6]
C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2	DM73ZMG	Discovery agent	N.A.	Investigative	[6]
C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2	DMDPBVS	Discovery agent	N.A.	Investigative	[6]
C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2	DMPZ4VB	Discovery agent	N.A.	Investigative	[6]
C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2	DMZWMV0	Discovery agent	N.A.	Investigative	[6]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	DMSIGJW	Discovery agent	N.A.	Investigative	[6]
C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2	DM45ZLW	Discovery agent	N.A.	Investigative	[6]
GPYRMEHFRWGSPPKD-NH2	DMLRTPH	Discovery agent	N.A.	Investigative	[2]
MK-10	DMI7859	Discovery agent	N.A.	Investigative	[7]
MK-11	DM4FG32	Discovery agent	N.A.	Investigative	[7]
MK-9	DMKEG2B	Discovery agent	N.A.	Investigative	[5]
MT-II	DMKT1DA	Female sexual arousal dysfunction	HA01.1	Investigative	[8]
NDP-SYSMEHFRWGKPVG	DMRV16G	Discovery agent	N.A.	Investigative	[2]
SHU9119	DMT62LS	Discovery agent	N.A.	Investigative	[9]
Tic-D-Phe-Arg-2-Nal-NHCH3	DMMFCHU	Discovery agent	N.A.	Investigative	[10]

References

• [1] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [2] Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
• [3] Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73.
• [4] Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
• [5] Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
• [6] Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
• [7] Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50.
• [8] Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58.
• [9] Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002 Oct;46(10):2765-75.
• [10] Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5.